XYLYX BIO releases highly physiologic 2D substrates for improved antifibrotic drug discovery
- Wednesday, August 26, 2020, 7:15
- Business
- Add a comment
NEW YORK, Aug. 26, 2020 /PRNewswire/ — New York-based Xylyx Bio, a leader in advanced disease models, today announced the release of normal and fibrotic NativeCoat™ human lung- and liver-specific ECM substrates for antifibrotic drug discovery to increase predictiveness of high throughput…
About the Author
adminasapcorp has written 39628 stories on this site.